Boston Scientific kept by JMP at under perform

Boston Scientific Corp. was maintained by JMP Securities analyst Robert Faulkner at under perform with a price target on the stock of $27 per share, noting the FDA has altered the Taxus label to include mention of higher occurrence of non Q-wave MI (heart attack) in patients with multiple Taxus stents compared to multiple bare metal stents. Boston Scientific shares Wednesday were down $1.95, or 7.44%, at $24.26 on volume of 17,050,700 shares versus the three-month running average of 3,827,090 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.